NCT

Intercont (Cayman) Limited

$2.70

-$0.03 (-1.03%)Today

-$0.18 (-6.25%)After Hours

Key Statistics

Market cap27.78M

Price-Earnings ratio—

Dividend yield—

Average volume263.9K

High today$3.05

Low today$2.82

Open price$2.85

Volume660.83K

52 Week high$121.60

52 Week low$1.30

Company Profile

Description

Intercont (Cayman) Limited, through its subsidiaries, provides maritime shipping services in Hong Kong and internationally. The company offers time charter and vessel management services worldwide. It is also involved in the processing of pulp, paper, and paperboard products. Intercont (Cayman) Limited was incorporated in 2023 and is based in Causeway Bay, Hong Kong.

Sector

Industrials

Industry

Marine Shipping

CEO

Ms. Qingyuan Wang

Website

intercontcayman.com

Company Profile

Description

Sector

Industrials

Industry

Marine Shipping

CEO

Ms. Qingyuan Wang

Website

intercontcayman.com

NCT

Key Statistics

Company Profile

Company Profile

Recent News

Infiniti Indah Announces the Return of Pesta Kuantan 188 from 31 July to 2 August.

Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs

Top Premarket Decliners

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Intercont (Cayman) Limited Announces Pricing of $6.32 Million Public Offering

MediciNova CEO Provides Shareholder Update

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent News

Company Profile

Recent News

Infiniti Indah Announces the Return of Pesta Kuantan 188 from 31 July to 2 August.

Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs

Top Premarket Decliners

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Intercont (Cayman) Limited Announces Pricing of $6.32 Million Public Offering

MediciNova CEO Provides Shareholder Update

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series